Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice

Experimental and Toxicologic Pathology

Volumn 63, Issue 3, 2011, Pages 215-219

  An, Yi ^a   Xin, Hui ^a   Yan, Wei ^b   Zhou, Xiaoxu ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Lipid peroxidation; Nephrotoxicity; Nitrosative stress; Oxidative stress; Pravastatin

Indexed keywords

3 NITROTYROSINE; CATALASE; CISPLATIN; CREATININE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; NITROGEN; PRAVASTATIN; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HISTOPATHOLOGY; MOUSE; NEPHROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOOD UREA NITROGEN; BLOTTING, WESTERN; CISPLATIN; CREATINE; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED ICR; OXIDATIVE STRESS; PRAVASTATIN;

MUS;

EID: 79951677271     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2009.12.002     Document Type: Article

References (30)

1. Alvarez B., Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acid 2003, 25:295-311.
2. Arany I., Megyesi J.K., Kaneto H., Price P.M., Safirstein R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 2004, 287:F543-F549.
3. Baek S.M., Kwon C.H., Kim J.H., Woo J.S., Jung J.S., Kim Y.K. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003, 142:178-186.
4. Chester J.D., Hall G.D., Forster M. Protheroe AS. Systemic chemotherapy for patients with bladder cancer-current controversies and future directions. Cancer Treat Rev 2004, 30:343-358.
5. Chirino Y.I., Hernandez-Pando R., Pedraza-Chaveri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 2004, 4:20-29.
6. Chirino Y.I., Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009, 61(3):223-242.
7. Corsini A., Maggi F.M., Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995, 31:9-27.
8. Daugaard G. Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 1990, 37:1-12.
9. Eiserich J.P., Patel R.P., O'Donnell V.B. Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. Mol Aspects Med 1998, 19:221-357.
10. Guyton K., Liu Y., Gorospe M., Xu Q., Holbrook N. Activation of mitogen-activated protein kinase by H2O2. J Biol Chem 1996, 271:4138-4142.
11. Jordan P., Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000, 57:1229-1235.
12. Kawai Y., Taniuchi S., Okahara S., Nakamura M., Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005, 28:1385-1388.
13. Lebwohl D., Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998, 34:1522-1534.
14. Lowry O., Rosenbraugh N., Farr L., Rondall R. Protein measurement with the folin-phenol reagent. J Biol Chem 1951, 193:265-275.
15. Madias N.E., Marrington J.T. Platinum nephrotoxicity. Am J Med 1978, 65:307-314.
16. Matsushima H., Yonemura K., Ohishi K., Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998, 131:518-526.
17. Pectasides D., Pectasides E., Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007, 33:177-190.
18. Ramesh G., Reeves W.B. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005, 289:F166-F174.
19. Saad S.Y., Al-Rikabi A.C. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 2002, 48:42-48.
20. Sadzuka Y., Shoji T., Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992, 43:1873-1875.
21. Saleh S., El-Demerdash E. Protective effects of l-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005, 97:91-97.
22. Screnci D., McKeage M.J. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 1999, 77:105-110.
23. Simins M. Molecular multitasking: statins lead to more arteries, less plaque. Nat Med 2000, 6:965-966.
24. Srivastava R.C., Farookh A., Ahmad N., Misra M., Hasan S.K., Husain M.M. Evidence for the involvement of nitric oxide in cisplatin induced toxicity in rats. Biometals 1996, 9:139-142.
25. Stewart D.J., Benjamin R.S., Luna M. Human tissue distribution of platinum after cis-diaminedichloroplatinum. Cancer Chemother Pharmacol 1982, 10:51-54.
26. Sun Y., Oberley L.W., Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988, 34:497-500.
27. Taguchi T., Nazneen A., Abid M.R., Razzaque M.S. Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol 2005, 148:107-121.
28. Vermeulen N.P., Baldew G.S. The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol 1992, 6:1193-1199.
29. Weijl N.I., Cleton F.J., Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 1997, 23:209-240.
30. Zunino F., Tofanetti O., Besati A., Cavalletti E., Savi G. Protective effect of reduced glutathione against cis-dichlorodiammine platinum (II)-induced nephrotoxicity and lethal toxicity. Tumori 1983, 69:105-111.